Longeveron Inc.

Follow the formal presentation. Should anyone require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Derek Cole of Investor Relations Advisory Solutions. Thank you. You may begin.

Thank you, operator. Good afternoon, everyone, and thank you for joining us today to review Longevron's 2025 first quarter financial results and business updates. After the U.S. markets closed today, we issued a press release with financial results for Q1 2020, which can be found under the investor section of the Longevron website. On the call today are Wael Hashad, Chief Executive Officer, Joshua O'Hare, Co-Founder, Chief Science Officer and Chairman of the Board, Natalia Agafonova, Chief Medical Officer, Lisa Locklear, Chief Financial Officer, and Devin Blass, Chief Technology Officer. As a reminder, during this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press release and risk factors discussed in the company's filings with the Securities and Exchange Commission, which we encourage you to review. Following the company's prepared remarks, we will open the call to questions from covering analysts. With that, let me hand the call over to Dr. Joshua Hare, founder and chairman of the board. Josh?

Thank you, Derek. Good afternoon, everyone, and thank you very much for joining us today. We greatly appreciate your interest in Longeviron. We are very pleased to update you on our continued successful progress advancing stem cell therapy with our lead product, Laromester Cell, for multiple chronic indications. Simply put, this period of the past two years to next year is the most exciting time in the company's history. Ten years ago, when I co-founded the company, our stem cell therapy vision was an academic idea. Today, we can see the possibility of our first BLA submission seeking approval for laromestrocell for HLHS. This directly reflects our mission, seeking to help patients and families through the application of stem cell research. In Alzheimer's disease, we've generated incredibly important clinical data supporting the therapeutic potential of laromestrocell in this devastating neurodegenerative disorder that leads to progressive memory loss and death and currently has very limited therapeutic options. This data has been accepted for presentation at multiple leading industry conferences and was published in the prestigious peer-reviewed journal Nature Medicine in the April 2025 issue. We were honored to also have the opportunity to discuss these phase two results in a recent article in Neurology Today. Our motivation and dedication to advancing stem cell therapy research has only been further invigorated by the reception to this data from the thought leader community. The next 12 to 18 months are potentially transformational period for Longevron with multiple critical milestones. and we are incredibly excited about the opportunity for this progress and to share the developments with you. I will now hand the call over to Wael. Wael?